Nelson Mullins advised MiCo Ltd (“MiCo”), a South Korea-based company listed on KOSDAQ, on its $45 million strategic investment and partnership with Trinity Biotech plc (Nasdaq: TRIB) (“Trinity”), a leading global diagnostic company. Following this investment, MiCo will hold 29.9% of the voting share capital of Trinity. In addition to the newly issued equity, Trinity has agreed to issue a seven-year, unsecured junior convertible note in the amount of $20 million to MiCo. MiCo was advised by Pacific General, a New York and Seoul based merchant banking and asset management firm, which initiated MiCo’s strategic investment in partnership with MiCo and will also act as investment manager to MiCo IVD Holdings, a MiCo investment vehicle.

This deal underlines Nelson Mullins’ skills across a number of multidisciplinary practice groups.

Completion of the deal is subject to customary approvals and is expected to close before the end of April 2022. The Nelson Mullins team was led by partners Jim Bartling, Brian Moore, and Gary Brown, senior associate Sarah Swerdloff and associate Amanda Chong from our Corporate Group. Additional input was also provided by partners Buzz Burwell, Adam Safwat, Nichole Hayden, John MacMaster and senior associate Drew Hermiller.